Howard Wessel is Director of Research and Development at Noveome Biotherapeutics, where he oversees preclinical development, drug characterization, formulation and release assay development. During his employment, he has gained valuable experience in the manufacturing and testing processes for Biologics, consistent with those specified by the FDA using current Good Manufacturing Practices (cGMP). Howard spent much of his early career in research and development at the University of Pittsburgh, Department of Ophthalmology where he specialized in corneal wound healing. Additionally, he has worked as a consultant for Generin Diagnostics and Genzyme Corporation developing enzyme assays to test and monitor patients with lysosomal storage disorders. Howard is co-author on several publications on corneal differentiation, neural protection and surrogate markers for Gaucher disease. At Noveome, he manages a team of people and projects with the goal to advance their primary drug candidate ST266.